Biotherapy Translational Medicine Center of West China Hospital is becoming a highly-regarded, comprehensive and multidisciplinary research center (Figure 1 ). Through the seamless integration of basic research, preclinical development, translational and clinical medicine, an efficient and fully integrated technology chain for the discovery and development of innovative drug candidates and new therapy has been established in a single institute. One mission of this center is to improve the treatment of major human diseases such as cancer, cardiovascular diseases, obesity, diabetes mellitus, infectious diseases (hepatitis, AIDS, tuberculosis, etc.), inflammatory diseases, neurological disease, as well as chronic autoimmune diseases. Focusing on more than 150 important targets, hundreds of projects for biologic drugs (such as gene and cell therapy, vaccines, monoclonal antibodies, recombinant proteins), synthetic small molecule drugs and small molecule natural products are ongoing.
The center boasts a prominent faculty of nearly 100 well-funded full professors, associate professors and assistant professors with diverse disciplines such as clinical medicine, biotechnology, structural biology, immunology, pharmacology, chemistry, formulations, drug delivery and material sciences. Every year the faculty obtains competitive grants from the government, including the National High Technology Research and Development Program (863 Program) or the Major State Basic Research Development Program (973 Program). Over 400 research papers are published in peer-reviewed international journals every year, including such top journals as New Engl J Med, Nat Rev Drug Discovery, Dev Cell, Nat Chemical Biol, Nature Med, Mol Cell, Proc Natl Acad Sci USA, Cancer Res and Lancet Neurol. To date, the platform has licensed over 150 patents to the commercial sector throughout China. Furthermore, 45 potent candidate drugs, including synthetic and natural small molecular drugs, gene and cell therapy, vaccine, monoclonal antibodies and recombinant proteins, thus far have been transferred to over 30 pharmaceutical companies for commercial development. The candidate drugs are those for the treatment of cancer, diabetes, autoimmune diseases, fibrosis, Hepatitis B/C and HIV.
The platform also provides both key technological services and integral solutions in R&D for other institutions and companies, including:
(1) Drug target identification and drug screening. The platform has established multiple sub-platforms for R&D screening of novel molecules, such as genomics, proteomics, structural biology, bioinformatics, computer-aided drug design, screening and synthesis of small molecule chemical drugs and the separation and purification of active natural products.
(2) Pilot-scale production. Six GMP-level facilities for pilot-scale production of adenoviral vectors, vaccines, DNA plasmids, recombinant proteins and nanoparticles have been established. For example, the pilot-scale production of DNA plasmids provides 5,0008,000 doses for early phase clinical trials.
(3) Pharmacodynamics & pharmacokinetics. Three separate experimental animal facilities can maintain up to 60,000 mice. At full capacity, 300 drug candidates can be evaluated at the same time. To date, there have been over 100 different preclinical disease models established at these facilities.
(4) Pre-clinical safety evaluation. The animal center has currently obtained international "AAALAC" accreditation.
The GLP facility can maintain up to 500 monkeys. Various toxicity studies including single dose toxicity, repeated dose toxicity, reproductive and developmental toxicity, genotoxicity, carcinogenicity, immunogenicity and pharmacokinetic/toxicokinetic (PK/TK) analyses are all performed.
(5) Clinical trials. Clinical trials testing gene and cell therapy, cytokines and anti-cytokines, monoclonal antibodies, chemotherapy and targeted small molecule drugs are conducted in the clinical units of West China Hospital with 4,300 beds.
(6) Graduate programs. The platform also is an educational center. Every year the platform enrolls about 150 Ph.D. and 100 M.S. students for different academic programs, as well as nearly 100 M.S. graduate students for pharmaceutical engineering programs.
